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E-mail address: sasa.filipovic@imi.bg.ac.rs (S.R. FiliObjective: Low-frequency (61 Hz) rTMS (LF-rTMS) can reduce excitability in the underlying cortex and/or
promote inhibition. In patients with Parkinson’s disease (PD) several TMS elicited features of motor cor-
ticospinal physiology suggest presence of impaired inhibitory mechanisms. These include shortened
silent period (SP) and slightly steeper input–output (I–O) curve of motor evoked potential (MEP) size than
in normal controls. However, studies of LF-rTMS effects on inhibitory mechanisms in PD are scarce.
Objective: In this companion paper to the clinical paper describing effects of four consecutive days of
LF-rTMS on dyskinesia in PD (Filipović et al., 2009), we evaluate the delayed (24 h) effects of the LF-rTMS
treatment on physiological measures of excitability of the motor cortex in the same patients. There are
very few studies of physiological follow up of daily rTMS treatments.
Methods: Nine patients with PD in Hoehn and Yahr stages 2 or 3 and prominent medication-induced dys-
kinesia were studied. This was a placebo-controlled, crossover study, with two treatment arms, ‘‘real”
rTMS and ‘‘sham” rTMS (placebo). In each of the treatment arms, rTMS (1800 pulses; 1 Hz rate; intensity
of the real stimuli just-below the active motor threshold) was delivered over the motor cortex for four
consecutive days. Motor cortex excitability was evaluated at the beginning of the study and the next
day following each of the four-day rTMS series (real and sham) with patients first in the practically
defined ‘‘off” state, following 12 h withdrawal of medication, and subsequently in a typical ‘‘on” state fol-
lowing usual morning medication dose.
Results: The SP was significantly longer following real rTMS in comparison to both baseline and sham
rTMS. The effect was independent from the effects of dopaminergic treatment. There was no difference
in MEP size, rest and active motor threshold. The I–O curve, recorded from the relaxed muscle, showed
a trend towards diminished slope in comparison to baseline, but the difference was not significant. There
was no consistent correlation between prolongation of SP and concomitant reduction in dyskinesia fol-
lowing real rTMS.
Conclusions: Low-frequency rTMS delivered over several consecutive days changes the excitability of
motor cortex by increasing the excitability of inhibitory circuits. The effects persist for at least a day after
rTMS.
Significance: The results confirm the existence of a residual after-effect of consecutive daily applications
of rTMS that might be relevant to the clinical effect that was observed in this group of patients and could
be further exploited for potential therapeutic uses.
 2010 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights
reserved.1. Introduction
A number of studies have shown that rTMS can modulate the
excitability of the motor cortex beyond the period of stimulation.f Clinical Neurophysiology. Publish
xperimental Clinical Neuro-
otica 4, P.O. Box 102, 11129
2643691.
pović).Increased excitability usually occurs if higher frequencies (above
5 Hz) are used (Pascual-Leone et al., 1994), while decreases in
excitability have been shown not only in the motor cortex, but also
in the visual cortex, if low-frequency (61 Hz) trains are given for
5 min or more (Chen et al., 1997; Boroojerdi et al., 2000; Cantello
et al., 1991; Maeda et al., 2000; Muellbacher et al., 2000). The
mechanism involved is not known, but the stimulation rate is sim-
ilar to that producing long-term depression in animal studies (re-
viewed in Post et al., 1999; and Ziemann, 2004). In addition, theed by Elsevier Ireland Ltd. All rights reserved.
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but can be also detected at distant though connected sites within
the same functional circuit both at cortical and subcortical levels
(Fox et al., 1997; Gerschlager et al., 2001; Siebner et al., 2003).
There are reports of a beneficial clinical effect of low-frequency
rTMS (LF-rTMS) on diseases with increased cortical excitability
such as focal hand dystonia (Siebner et al., 1999, 2003) and
epilepsy (Tergau et al., 1999; Fregni et al., 2006). There is also
evidence that the physiological effect in patients may even be
stronger than that seen in healthy subjects (Siebner et al., 1999,
2003). In patients with Parkinson’s disease (PD) several TMS
elicited features of motor corticospinal physiology suggest that
inhibitory mechanisms are impaired. These include shortened
silent period (SP) and slightly steeper input–output (IO) curves of
motor evoked potential (MEP) size than in normal controls –
changes that are typically ameliorated by levodopa/dopaminergic
medication in concert with relief of clinical symptoms (reviewed
in Cantello et al., 2002; and Lefaucheur, 2005).
We have recently reported a beneficial clinical effect of LF-rTMS
on medication-induced dyskinesia in PD (Filipović et al., 2009). As
a part of that study we also recorded neurophysiological parame-
ters of cortical excitability. This provided an opportunity to test
whether in a group of patients with a condition characterized by
reduced cortical inhibition, LF-rTMS applied over motor cortex
for several consecutive days is able to induce a sustained and mea-
surable change in the excitability of the motor cortex and in partic-
ular increase the excitability of inhibitory mechanisms.2. Methods
2.1. Design of study
This was a placebo-controlled, single-blinded, crossover study,
with each treatment arm lasting 1 week, and each period of treat-
ment separated by a minimum of 2 weeks (Fig. 1). The two treat-
ment arms consisted of four successive daily visits (from Monday
to Thursday) each, when either ‘‘real” rTMS or ‘‘sham” rTMS (pla-
cebo) were delivered. The same type of rTMS was used throughout
successive 4 days and the order of the treatments was randomly
assigned. The time of day for treatment visits was kept constant
for each patient.
The baseline evaluation session (e0) was during a week preced-
ing the first treatment session. The treatment evaluation sessions
(e1 and e2) were on the first Friday after the end of the each rTMS
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Fig. 1. Design of the study. The rTMS, either real of sham (placebo), was delivered in two
before the first rTMS treatment series, the first/baseline evaluation session (e0) was sched
rTMS session (i.e. Friday) of the each rTMS series, respectively. At each evaluation session
first with patients in practically defined ‘OFF’ state, and then once patients achieved a srespectively. At each evaluation session, a set of clinical and neuro-
physiological tests was carried out with patients in so called prac-
tically defined ‘off’ state, following at least 12 h (overnight) refrain
from anti-parkinsonian medication. Following this, a second set of
tests was carried out once patients achieved a stable ‘‘on” state,
after taking their usual morning medication dose. Since the study
was designed to test the effect of rTMS on medication-induced dys-
kinesia in Parkinson’s disease, each evaluation visit also included a
clinical assessment. Patients were examined using Unified PD Rat-
ing Scale (UPDRS) Motor Section (Part 3). In addition, in the ‘‘on”
state, dyskinesias were rated off-line from videotapes using the
Clinical Dyskinesia Rating Scale (CDRS) developed by Hagell and
Widner (1999). The most severe involuntary movements observed
are scored from 0 (none) to 4 (extreme), in each of the seven body
areas: face, neck, trunk, and four extremities, separately for
hyperkinesias (i.e., choreic movements) and dystonia. The clinical
results have been already published (Filipović et al., 2009). Ses-
sions were always organised in the morning hours at the earliest
convenience to the patient.
2.2. Patients
Nine right-handed, non-demented patients with idiopathic PD,
satisfying United Kingdom Parkinson’s Disease Society Brain Bank
criteria (Gibb and Lees, 1988), manifesting obvious dyskinesias
present most of the day were studied. They were recruited through
the outpatient department of the Frenchay Hospital (Bristol, UK).
All patients were on the fixed dose of their usual anti-parkinsonian
medication for at least 1 month prior to starting the study until the
end of the study. Informed consent was obtained from each patient
according to the Declaration of Helsinki, and study protocol was
approved by the Frenchay Local Research Ethics Committee. The
details of patients’ characteristic are presented on Table 1. They
were essentially the same patients as in Filipović et al. (2009) pa-
per, but without one patient whose neurophysiological data had
to be discarded because inability to relax adequately due to exces-
sive dyskinesias in the ‘‘on” phase.
2.3. Transcranial magnetic stimulation (TMS)
All transcranial magnetic stimulations, either single or repeti-
tive, were performed with Magstim Rapid Transcranial Magnetic
Stimulator (Magstim Company, Dyfed, UK). For ‘‘real” TMS a stan-
dard Magstim’s 70 mm figure-of-eight coil was used. The ‘‘sham”
rTMS was carried out with Placebo Coil (Magstim Company) thatCl Nf Cl Nf Cl Nf











four-day (from Monday to Thursday) long series (rTMS1 and rTMS2). Within a week
uled. Subsequent evaluation sessions (e1 and e2) were on the next day after the last
, two identical sets of clinical (Cl) and neurophysiological (Nf) tests were carried out,



















1 M 66 8 AR 31 16 15 L 350 1150
2 F 48 8 AR&T 32 11 9 R 350 650
3 F 71 22 T&AR 63 23 23 R 100 600
4 F 73 18 T&AR 50 33 33 L 100 700
5 M 48 16 T&AR 60 12 26 R 300 900
6 F 61 17 AR&T 49 22 20 L 100 600
7 M 64 16 AR 40 24 10 R 250 1400
8 M 71 11 AR 37 11 24 L 325 850
9 M 69 14 AR 42 19 28 L 200 950
M – male, F – female, AR – akinetic-rigid, T – tremor, UPDRS III – Unified Parkinson’s Disease Rating Scale Part 3 (Motor Score); CDRS – Clinical Dyskinesia Rating Scale,
OFFMED – off medication, ONMED – on medication, R – right, L – left.
a At baseline evaluation.
b Anti PD medication dosage is expressed as levodopa equivalent following published formulas: 1 mg pergolide = 1.05 mg pramipexole = 6 mg ropinirole = 1.5 mg
cabergoline = 100 mg levodopa (Grosset et al., 2004).
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al” coil but no effective magnetic field was generated. The hemi-
sphere contralateral to the more severely affected side was target
in all cases.
2.3.1. Neurophysiological assessment of cortical excitability
Cortical excitability was evaluated using single-pulse TMS. The
target muscle was the first dorsal interosseous muscle (FDI). At the
beginning of each experiment the optimal scalp site (‘‘hot-spot”)
and the resting motor threshold (rMT) for FDI were determined fol-
lowing a standard procedure (Rossini et al., 1994). The coil position
was marked on the head and its coordinates on midsagital (na-
sion–inion line) and biauricular (line connecting external auditory
meati) axes in relationship to the vertex were recorded. In order to
ensure consistent positioning of the coil throughout the experi-
ment the same coordinates were used in further sessions. The
hot-spot and MT finding procedures were replicated at each first
treatment session (Mondays) and each evaluation session (Fridays)
to check for consistency of coil positioning and MT changes follow-
ing investigated procedures, respectively. No differences in hot-
spot position were found at any of these occasions.
Neurophysiological testing was carried out first with FDI in
complete rest. Ten stimuli were delivered at TMS intensities of
110%, 120%, 130%, and 150% rMT, each. Next, participants were
asked to maintain voluntary contraction during TMS delivery. Ser-
ies of ten stimuli of 120% rMT intensity were delivered during each
of three different levels of background contraction – ‘mild’, ‘moder-
ate’, and ‘maximal’. With the help of a custom made visual feed-
back device, participants were asked to maintain contraction of
target FDI muscle either at 20–30% of the maximal voluntary con-
traction (MVC) strength (‘mild’ condition), 50–60% MCV (‘moder-
ate’), or 90–100% MCV (‘maximal’). The MVC was determined
beforehand and subjects trained to maintain required levels of
contraction.
The peak-to-peak amplitude of each MEP was measured and the
mean MEP amplitude was calculated separately for each condition.
Also, in the conditions with voluntary contraction, the ‘‘silent-per-
iod” (SP) offset latency was measured from single traces and then
averaged for each condition. The SP offset latency was determined
as either the latency of the onset of a burst of EMG activity reach-
ing at least 75% of the pre-stimulus background activity and lasting
at least 20 ms, or the latency of the onset of continuous EMG
activity.
2.3.2. Low-frequency rTMS
During LF-rTMS three series of 600 stimuli of 1 Hz rate, with
one-minute breaks in between, were applied during each session(1800 stimuli in total, duration 32 min). Stimulation variables were
in accordance with published safety recommendations (Wasser-
mann, 1998). The intensity was set individually to be just below
active motor threshold (aMT). The aMT was determined with the
target muscle maintaining 20% of the maximal voluntary contrac-
tion (MCV) strength and was defined as the minimum stimulator
intensity capable to evoke a MEP of 200–300 lV in amplitude at
least in 50% of 10 consecutive trials (Rothwell et al., 1999). The
aMT values were typically equal or below the 90% of resting motor
threshold (rMT).2.4. Data analysis
From recoded data several outcome measures were derived:
rest and active motor thresholds (rMT and aMT), rest MEP (mea-
sured with 120% rMT TMS intensity), MEP input–output (I–O)
curve (MEPs measured with TMS intensities of 110%, 120%, 130%,
and 150% rMT, with FDI muscle at rest), MEP facilitation with vol-
untary contraction, and silent period (SP). For the later two, volun-
tary MEP facilitation and SP, the results were analysed in
relationship to the level of the background muscle contraction
(measured as mean of rectified EMG for 50 ms interval before
TMS pulse) regardless of the exact instruction set during which
the measurement was made. The levels of the background muscle
contraction were grouped into three levels: mild (10–33% of the
maximal voluntary contraction (MCV)), moderate (34–66% MCV)
and strong (67–100% MCV).
Data were analysed two-fold in a pair-wise fashion. Results ob-
tained after one of the rTMS interventions (i.e. either real or sham)
were first compared with results at baseline, and then with each
other. For statistical assessment two-way and three-way repeated-
measures analyses of variance (ANOVA) were used with factors
rTMS type (real vs. sham) and dopaminergic treatment status (off
vs. on medication, OFFMED and ONMED, respectively), as well as
TMS intensity or level of background contraction, where appropri-
ate. Results were considered as significant if P < 0.05. Given that
comparisons with baseline were planned hypothesis-driven, i.e.
we wanted to check whether 1 Hz rTMS could promote inhibitory
mechanism manifested by shortening of SP and/or diminution of
MEP, one-tailed directional probability was used. In contrast, since
there was a possibility for a placebo effect of sham stimulation mim-
icking the expected effect of real stimulation, no reliable hypothesis
could be formed whether TMS variables would be in any way differ-
ent following real and sham rTMS, and thus for real vs. sham compar-
isons two-tailed non-directional probability was used.
Due to the non-parametric nature of clinical measures used,
correlations between clinical and neurophysiological data were
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tion method with significance set at P < 0.05 level. Given that this
was an exploratory study, no adjustments for multiple measure-
ments were applied.3. Results
Questioned at the end of their participation in the study, none of
the patients were able to identify which type of rTMS (i.e. whether
real or sham) was delivered in each of the treatment sessions.
3.1. Neurophysiology data
3.1.1. Motor thresholds
There was no difference in rMT across all conditions regardless
whether recorded on or off medication and at baseline or after real
or sham rTMS (Table 2). Equally, there was no difference in aMT
across all conditions (Table 2).
3.1.2. MEP at rest and during voluntary activation
MEP at rest in OFFMED condition was slightly lower after real
rTMS than it was at baseline and after sham rTMS, while in ONMED
condition there was no obvious difference (Fig. 2, Table 2). The data
were analysed by two-way repeated measures ANOVA with factors
rTMS type (i.e. baseline vs. real or sham, and real vs. sham), and
medication status (i.e. OFFMED vs. ONMED). No significant effect
of any of the two factors and their interactions was found for any
of the comparisons (F(1,8) < 1.00, P > 0.1, in all cases). Only for
baseline vs. real rTMS comparison the effect of rTMS type
(F(1,8) = 2.63) was slightly stronger (P = 0.072), while post-hoc
least-square difference (LSD) pair-wise test showed as significant
(P = 0.03) baseline vs. real rTMS difference in MEP in OFFMED
phase.
MEP facilitation during various levels of voluntary contraction
was analysed by three-way repeated measures ANOVA with fac-Table 2
Motor thresholds at rest (rMT) and during activation (aMT), and MEP size at rest (values
Baseline real rTMS
OFFMED ONMED OFFMED
rMTa 48.7 ± 9.8% 50.6 ± 10.7% 49.0 ± 8.7%
aMTa 43.7 ± 7.8% 43.6 ± 7.7% 43.2 ± 8.0%
MEPb 422.3 ± 307.0 349.7 ± 244.9 283.2 ± 111.2
a Motor threshold values are percentages of the stimulator output.
b MEP amplitudes are expressed in lV.






















Fig. 2. MEP facilitation during various levels of voluntary contraction. Presented are grou
real rTMS in ONMED condition. No major difference and large overlaps between respo
recorded with different levels of background contraction.tors rTMS type, medication status, and contraction level (i.e. rest vs.
mild vs. moderate vs. strong). MEP recruitment curves showed
no major differences regardless of the medication status and
whether recorded at baseline or after either real or sham rTMS type
(Fig. 2, Table 3). Only contraction level and interactions between all
three factors had significant effect in all pair-wise comparisons due
to significant differences between MEP size at rest and MEP sizes at
all three levels of contraction and between MEP size at mild con-
traction and MEP sizes at moderate and strong contractions; there
was no significant difference between MEP sizes at moderate and
strong contractions.3.1.3. I–O curve
In the OFFMED condition, the I–O curve following real rTMS was
slightly less steep than at baseline or after sham rTMS (Fig. 3). We
did not formally calculate the slope but the I–O curves were ana-
lysed by three-way repeated measures ANOVAs (Table 3) with fac-
tors rTMS type, medication status, and test TMS intensity level (i.e.
110% vs. 120% vs. 130% vs. 150% rMT). When baseline and real
rTMS were compared, the rTMS type and interaction of all three fac-
tors showed an effect of borderline significance (for both, P = 0.05),
and in particular MEP sizes at 120% rMT and 130% rMT intensities
off medication, and at 150% rMT on medication were significantly
smaller (Post-hoc LSD test, P = 0.03, 0.007, and 0.03, respectively).
No other comparison showed significant effects.3.1.4. Silent period
In one patient silent period (SP) could not be reliably deter-
mined due to excessive rest tremor in off condition. Therefore,
analyses were carried out on data from eight patients (Fig. 4, Ta-
ble 3). The SP was analysed by three-way repeated measures ANO-
VA with factors rTMS type, medication status, and contraction level.
As expected, SP was longer in ONMED than in OFFMED condition.
In addition, level of background contraction had significant effect
as well; the SP was progressively shorter with higher levels ofare presented as mean ± SD), in OFFMED and ONMED state.
sham rTMS
ONMED OFFMED ONMED
49.1 ± 8.6% 49.2 ± 8.5% 49.3 ± 8.5%
43.0 ± 7.9% 43.4 ± 7.7% 43.6 ± 7.7%
c 300.5 ± 155.0 410.6 ± 244.7 377.9 ± 245.6






rest mild moder. strong
p means with standard errors. Slightly lower MEP size can be seen at rest following
nses at baseline and following both real and sham rTMS can be seen in MEP sizes
Table 3
Results of ANOVAs on silent period (SP), MEP facilitation with voluntary muscle contraction, and input–output (IO) MEP curve.
Factors Interactions
rTMS type (1) on/off state (2) Muscle contraction (3) 1  2 1  3 2  3 1  2  3
SP
Baseline vs. F = 3.728 F = 9.631 F = 26.248 F = 0.339 F = 4.624 F = 1.281 F = 2.922
real rTMS P = 0.047 P = 0.009 P < 0.001 P = 0.289 P = 0.014 P = 0.154 P = 0.043
Baseline vs. F = 1.448 F = 19.162 F = 21.802 F = 0.381 F = 0.210 F = 4.662 F = 1.477
sham rTMS P = 0.134 P = 0.002 P < 0.001 P = 0.278 P = 0.406 P = 0.014 P = 0.131
Real rTMS vs. F = 7.318 F = 10.286 F = 32.246 F = 0.010 F = 1.102 F = 4.271 F = 1.850
sham rTMS P = 0.030 P = 0.015 P < 0.001 P = 0.924 P = 0.360 P = 0.036 P = 0.194
MEP facilitation
Baseline vs. F = 0.004 F = 0.735 F = 4.598 F = 2.298 F = 0.784 F = 1.007 F = 4.678
real rTMS P = 0.475 P = 0.208 P = 0.006 P = 0.084 P = 0.257 P = 0.203 P = 0.005
Baseline vs. F = 2.167 F = 0.186 F = 4.073 F = 0.745 F = 1.183 F = 0.609 F = 2.371
sham rTMS P = 0.090 P = 0.339 P = 0.009 P = 0.207 P = 0.168 P = 0.308 P = 0.048
Real rTMS vs. F = 1.364 F = 3.800 F = 4.185 F = 0.704 F = 0.047 F = 1.764 F = 1.251
sham rTMS P = 0.276 P = 0.087 P = 0.016 P = 0.426 P = 0.986 P = 0.181 P = 0.313
IO MEP (TMS intensity [3])
Baseline vs. F = 3.375 F = 0.721 F = 25.614 F = 0.064 F = 0.728 F = 1.248 F = 2.278
real rTMS P = 0.052 P = 0.210 P < 0.001 P = 0.403 P = 0.273 P = 0.157 P = 0.053
Baseline vs. F = 0.178 F = 0.497 F = 46.203 F = 0.084 F = 1.981 F = 0.476 F = 0.666
sham rTMS P = 0.342 P = 0.250 P < 0.001 P = 0.389 P = 0.072 P = 0.351 P = 0.290
Real rTMS vs. F = 0.151 F = 1.069 F = 37.590 F = 0.028 F = 1.680 F = 2.462 F = 0.926
sham rTMS P = 0.707 P = 0.331 P < 0.001 P = 0.871 P = 0.198 P = 0.087 P = 0.443

























Fig. 3. Input–output (I–O) curves. Presented are group means with standard errors. Lower MEP sizes can be seen following real rTMS in responses recorded with single-pulse
TMS intensities of 120% and 130% of rMT.
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was also significant although not for baseline vs. real rTMS.
Following real rTMS the SP was significantly longer than both at
baseline and following sham rTMS and the effect was independent
of medication status while showing some interaction with contrac-
tion levels but only for baseline vs. real rTMS comparison (Table 3).
Post-hoc pair-wise LSD test (with all three factors) showed as sig-
nificant baseline vs. real rTMS difference at mild, moderate, and
strong levels of contraction in OFFMED condition (P = 0.00002,
0.00005, and 0.01, respectively), and at mild and strong levels of
contraction in ONMED condition (P = 0.00005 and 0.0015, respec-
tively). For real vs. sham rTMS comparison, the difference was sig-
nificant at mild and moderate levels of contraction in OFFMED
condition (P = 0.004 and 0.029, respectively), and at mild and
strong levels of contraction in ONMED condition (P = 0.029 and
0.034, respectively). No significant effect of order of rTMS series(i.e. whether real or sham was first) on SP prolongation following
real rTMS in comparison to baseline was found. This was tested
by the Mann–Whitney U test for each of the medication states
and contraction levels separately.
3.1.5. Clinical variables – neurophysiology interaction
Patients reported no side effects following rTMS. As already re-
ported (Filipović et al., 2009), rTMS did not have any adverse ef-
fects on patients’ motor functions and other PD symptoms – total
UPDRS score and Motor Section score (both in ON phase) did not
differ after real and sham rTMS.
As it was reported (Filipović et al., 2009), following real rTMS,
scores on dyskinesia scale (CDRS) changed significantly in compar-
ison to the baseline while following sham rTMS the change was not
significant. However, on direct comparison, difference in CDRS
scores following real and sham rTMS although obvious was not sig-
Fig. 4. Silent period during various levels of voluntary contraction. Presented are group means with standard errors. Longer SP duration can be seen following real rTMS in
responses recorded with different levels of background contraction in both OFFMED and ONMED conditions.
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scores in comparison to baseline in the subpopulation of patients
whose SP data were reported in this study (N = 8) was 8.0% (SD
7.9), which was in keeping with the reduction reported for the
whole group (N = 10, 8.3%, SD 8.3; Filipović et al., 2009). In compar-
ison to baseline, seven patients had reduced CDRS scores following
real rTMS and in one the score was unchanged.
In order to check whether any clinical factors influenced SP
measurements in this study, correlations were analysed between
selected SP variables and relevant clinical variables. The SP vari-
ables were SP offset latencies at baseline and the SP offset latency
change following real rTMS (calculated as a difference between
measurements after real rTMS and at baseline), for all three levels
of contraction. The clinical variables were age, duration of disease,
UPDRS scores off and on medication at baseline, CDRS scores at
baseline, and medication level (total daily levodopa equivalents).
The only consistent correlation was between UPDRS scores on
medication and SP offset latencies at baseline (Table 4). The higher
the UPDRS scores, the later the SP offset. The correlations were sig-
nificant for mild and moderate levels of background contraction for
SP offset latencies measured both in off and on medication states.
There were two further isolated correlations as well. Duration of
the disease correlated with SP offset latency at baseline in off med-
ication state when the background contraction was moderate. The
SP offset latency change following real rTMS correlated negatively
with the amount of total daily medication. Furthermore, correla-
tions were analysed between mentioned SP variables, on one side,
and CDRS scores following real rTMS and the change in CDRSTable 4
Results of Spearman Rank Order Correlation test for correlations between SP offset latency
and the difference between values recorded following real rTMS and at baseline were analy
are presented separately for medication conditions and levels of background contraction.
Medication status Baseline
Background contraction OFFMED ONMED
Mild Mod. Max. Mild Mod.
Age 0.26 0.24 0.04 0.52 0.61
UPDRS III off @ Baseline 0.38 0.59 0.59 0.40 0.52
UPDRS III on @ Baseline 0.83 0.83 0.69 0.74 0.71
PD duration 0.55 0.75 0.67 0.52 0.65
Daily medication 0.43 0.26 0.26 0.19 0.00
CDRS @ Baseline 0.19 0.19 0.05 0.33 0.31
CDRS diff. Real - Base 0.45 0.27 0.31 0.34 0.06
Mod. – Moderate; Max. – Maximal. UPDRS III – Unified Parkinson’s Disease Rating Scale P
at baseline evaluation session; CDRS – Clinical Dyskinesia Rating Scale; diff. Real – Base. –
baseline evaluation session.scores between baseline and post-real rTMS, on the other side (Ta-
ble 4). Only one isolated correlation was found to be significant.
The SP offset latency change following real rTMS, in on medication
state when the background contraction was mild, correlated with
the change in CDRS scores between baseline and post-real rTMS.4. Discussion
The key finding of this study is that, in PD patients, low-fre-
quency rTMS delivered for four consecutive days increases motor
corticospinal inhibition as indexed by a significant prolongation
of the SP and a trend towards a diminished slope of the MEP I–O
recruitment curve, which are detectable 24 h after the last rTMS
delivery. As far as we are aware, this is first demonstration of such
an extended effect of rTMS on cortical excitability in PD.
Traditionally, cortical excitability is measured as either the rest-
ing motor threshold (rMT) or motor evoked potential (MEP) size
(reviews in Pascual-Leone et al., 1998; and Fitzgerald et al.,
2002a). The effect of 1 Hz rTMS on rMT level in healthy subjects
was assessed in several studies (reviewed in Fitzgerald et al.,
2006). Most of them reported no change which is in keeping with
the results of this study.
Most of the studies investigating post-train effects of low-fre-
quency stimulation found that it reduced MEP size (amplitude,
area or recruitment curve) (reviewed in Fitzgerald et al., 2006).
However, the effect appears to be intensity related; almost all stud-
ies providing stimulation at relatively low stimulation intensities
(85–90% of rMT or 90% of active MT), comparable with intensitiesand clinical variables. The values of SP offset latencies recorded at baseline evaluation
sed. The R coefficients are presented and significant results are marked in bold. Results
Real rTMS – Baseline difference
OFFMED ONMED
Max. Mild Mod. Max. Mild Mod. Max.
0.31 0.29 0.48 0.53 0.17 0.24 0.65
0.59 0.05 0.05 0.33 0.12 0.26 0.52
0.48 0.24 0.24 0.36 0.48 0.29 0.05
0.65 0.10 0.07 0.48 0.05 0.19 0.47
0.07 0.33 0.43 0.05 0.74 0.50 0.59
0.14 0.38 0.59 0.48 0.14 0.29 0.62
0.16 0.52 0.39 0.36 0.87 0.63 0.63
art 3 (Motor Score); off – off medication; on – on medication; @ Baseline – Recorded
Difference between scores obtained at evaluation session following real rTMS and at
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Modugno et al., 2003; Brighina et al., 2005; Houdayer et al.,
2008). However, they were all single-session studies; the results
of this study suggest that by repeated application of low-frequency
rTMS over several days it is possible to elicit a modest but sustain-
able effect on cortical excitability even when using sub-threshold
TMS intensities.
There are no studies of the effect of LF-rTMS on MEP facilitation
during voluntary contraction. In the present group of PD patients
there were no significant changes following either real or sham
rTMS suggesting a lack of LF-rTMS effects on facilitatory corticospi-
nal mechanisms in PD. Relatively weak changes in MEP facilitation
with various levels of voluntary contractions found in this study
were in keeping with previously reported results in PD patients
(Valls-Solé et al., 1994).
Previous studies of 1 Hz rTMS effects on the SP in healthy sub-
jects provided conflicting results. Two studies reported a shorten-
ing (Fierro et al., 2001; Fitzgerald et al., 2004), three no change
(Fitzgerald et al., 2002b; Gilio et al., 2003; Modugno et al., 2003),
one a small increase (Daskalakis et al., 2006), and only one a clear
increase (Stinear and Byblow, 2004) of SP duration following a sin-
gle session of 1 Hz rTMS.
Data for PD are scarce. In a group of 12 PD patients off medica-
tion, about half-an-hour after single 20 min-long session of 0.5 Hz
rTMS applied at 80% rMT intensity (600 stimuli in total) over the
left primary motor cortical area, Lefaucheur et al. (2004) found sig-
nificant prolongation of the SP and increased short-latency intra-
cortical inhibition (SICI) in comparison to the pre-rTMS values;
sham rTMS did not elicit such changes. These results would be very
much complimentary with those from our study, suggesting that
even a single LF-rTMS session can prolong the SP in PD patients.
Apparently contradictory are the results from the Wagle-Shukla
et al. (2007) study. Using a comprehensive battery of TMS mea-
sures of cortical excitability, which included MEP at rest and MEP
I–O curve as well as SP, in 6 PD patients, they did not find any sig-
nificant change 24 h after 10 successive daily 15 min-long sessions
of 1 Hz rTMS applied at 90% rMT (900 stimuli) in comparison to the
pre-rTMS values. Interestingly, they found a significant reduction
of dyskinesia following rTMS treatment which was in keeping with
the clinical results of this study (Filipović et al., 2009).
The difference in results regarding SP between Wagle-Shukla
et al. (2007) and this study may be due to slight differences in
methodology. In our study twice as many stimuli were applied.
Longer duration rTMS trains may be necessary for physiological ef-
fects to be detectable after 24 h even if clinical effects are clearly
present. In addition, Lafaucheur et al. (2004), who also found SP
prolongation following slow rTMS, tested their patients in the off
phase. We tested our participants in a clearly defined off phase
and subsequently in the on phase following their usual morning
medication. Wagle-Shukla et al. (2007) carried out neurophysiol-
ogy testing after the levodopa challenge test using 125% of pa-
tients’ usual morning levodopa equivalent dose. Levodopa and
dopaminergic drugs prolong SP in healthy subjects (Ziemann
et al., 1997) and PD patients (Priori et al., 1994; Ridding et al.,
1995; Diószeghy et al., 1999; Strafella et al., 2000; Pierantozzi
et al., 2001). We also found a significant effect of levodopa and
dopaminergic medication on SP prolongation which was indepen-
dent from and statistically stronger than rTMS effect. It may be that
the magnitude of physiological response to higher doses of levo-
dopa used for levodopa challenge in Wagle-Shukla et al. (2007)
study blurred the effect of rTMS.
Siebner et al. (2000) reported a significant prolongation of the
SP following a single session of sub-threshold 5 Hz rTMS in non-
medicated PD patients but not in healthy subjects. This may sug-
gest an increased susceptibility towards inhibitory effects of rTMS
in PD, which extends beyond the range of rTMS frequencies knownto promote inhibitory mechanisms in healthy subjects. Increased
susceptibility to rTMS inhibitory effects has been already demon-
strated in another basal ganglia disorder, focal hand dystonia
(Siebner et al., 2003). This is an issue that requires further
investigation.
Although CDRS scores diminished following real rTMS and SP
offset latencies became longer in comparison to baseline, there
was no correlation between the two. This was surprising, since
both changes happened following the same intervention. The small
sample size might have precluded detection of a statistically signif-
icant link. Alternatively, the finding may indicate that SP duration
and dyskinesia are not causally related but rather are manifesta-
tions of close but not identical physiological processes.
In patients with PD several indices of motor cortex inhibition
are impaired. Apart from the most consistently reproduced finding
of shortened duration of the SP after TMS in patients when off
medication or when taking low levodopa doses (Cantello et al.,
1991; Priori et al., 1994; Nakashima et al., 1995; Valzania et al.,
1997; Diószeghy et al., 1999), reduced short-latency intra-cortical
inhibition (SICI) (Ridding et al., 1995; Hanajima et al., 1996; Stra-
fella et al., 2000) and long-latency afferent inhibition (LAI) (Sailer
et al., 2003; Tamburin et al., 2003) were also found. Low-frequency
rTMS in PD most likely does not affect only mechanisms responsi-
ble for SP generation but a range of different inhibitory mecha-
nisms, such as one responsible for SICI (Lefaucheur et al., 2004).
It may well be that dyskinesias are mostly mediated through
impairment in these other mechanisms thus explaining the lack
of correlation between SP prolongation and improvement of clini-
cal dyskinesia in this study. As a further proof for this, increased
SICI has been reported after subthalamic nucleus (STN) deep-brain
stimulation (DBS) (Cunic et al., 2002; Däuper et al., 2002; Pier-
antozzi et al., 2002) and similar findings were reported after inter-
nal globus pallidus DBS (Pierantozzi et al., 2002). In addition,
increased LAI was reported after STN DBS (Sailer et al., 2007). Both
DBS procedures are well known to be exceptionally effective in
calming dyskinesias in PD (Benabid, 2003; Anderson et al., 2005).
In healthy subjects, dopaminergic stimulation was found to en-
hance LF-rTMS induced motor cortex inhibition, measured by
changes in MEP amplitude (Lang et al., 2008). However, in this
study, medication status had no effect on rTMS variables and in
particular the rTMS induced SP prolongation was independent
from the medication effect, which also prolonged the SP. Our find-
ings were in keeping with previous findings of Morgante et al.
(2006) who used another non-invasive method to modulate motor
cortex excitability, paired-associated stimulation (PAS). While the
PAS method they used caused significant SP prolongation in
healthy subjects, it failed to do the same in PD patients; levodopa
prolonged the SP, but did not improve the response to PAS. The
lack of a modulatory effect of levodopa on the plasticity of inhibi-
tory systems may relate directly to the pathophysiology of dyski-
nesia in PD.
It has been shown that SP duration is sensitive to GABA-B mod-
ulation (Werhahn et al., 1999). It is thought that dopaminergic
medication influences SP duration by enhancing the post-synaptic
sensitivity to GABA (Beauregard and Ferron, 1991). The mechanism
through which LF-rTMS exercises its effect on cortical excitability
is not yet certain (Fitzgerald et al., 2006). Most likely, it is similar
to the mechanisms involved in the phenomenon of long-term
depression (LTD) seen in animal experiments (Ziemann, 2004).
The lack of statistical interactions between rTMS and medication
effects in this study suggests that two interventions change SP
duration through different mechanisms. This finding provides fur-
ther proof for the feasibility of therapeutical use of LF-rTMS.
An interesting finding of this study was that the severity of PD
motor symptoms affected SP duration. Higher UPDRS scores on
medication were significantly associated with longer SP duration
1136 S.R. Filipović et al. / Clinical Neurophysiology 121 (2010) 1129–1137both off and on medication. The physiological and clinical signifi-
cance of this relationship is not clear. Nevertheless, severity of
PD motor symptoms did not have any obvious effect on the princi-
pal finding of this study, the SP prolongation following real rTMS in
comparison to baseline. Other significant correlations between SP
duration and clinical variables were not consistent and most likely
were detected by chance due to multitude of comparisons.
Another interesting finding of this study is that the duration of
the SP in studied PD patients was significantly influenced by the
degree of contraction. It is commonly considered that in healthy
subjects, the degree of background contraction has little influence
on SP duration (e.g. Chen et al., 2008). This is certainly true for
higher intensities of stimulation, however, the available evidence
seems to suggest that at low stimulus intensities, at or below
120% MT, and with the explicit instruction given to the participants
to keep the contraction level constant, the SP gets progressively
shorter with increased background contraction (Cantello et al.,
1992; Wilson et al., 1993; Mathis et al., 1998; Filipović et al.,
2008). Results of this study suggest that the relationship might
be even more pronounced in PD or at least in a subset of PD pa-
tients displaying prominent dyskinesias as further manifestation
of impaired inhibitory mechanisms. This is an issue that may be
of interest for further studies.
Dopaminergic medication was shown to induce changes in cor-
tical interactions and plasticity (Mir et al., 2005; Morgante et al.,
2006). The rTMS in this study was delivered with patients on med-
ication. It is yet unknown whether the effects may be different and
even stronger if rTMS is delivered off medication. This issue re-
quires to be evaluated further.
Before concluding, it should be noted that in this study the
strength of rTMS pulses was relatively low. It was set for each pa-
tient separately to be just below active motor threshold (aMT) to
avoid patients perceiving the difference between ‘‘active” and
‘‘sham” sessions. However, weaker rTMS pulses induce weaker
physiological effects (Fitzgerald et al., 2002b) and it might well
be that with the same experimental setting as in this study stron-
ger rTMS would be able to induce more pronounced effects on cor-
tical excitability in general and inhibitory mechanisms in
particular. This is an issue that would require further studies.
The encouraging results of this study regarding both physiolog-
ical and clinical effects, suggest a need for further studies that
would systematically evaluate relevant methodological features
able to establish more prominent and longer lasting effects. That
is, clinical trials that would involve not only stronger TMS stimuli,
but also more days of rTMS and bilateral stimulation.
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MR, Hallett M, Katayama Y, Lücking CH, et al. Non-invasive electrical and
magnetic stimulation of the brain, spinal cord and roots: basic principles and
procedures for routine clinical application. Report of an IFCN committee.
Electroenceph Clin Neurophysiol 1994;91:79–92.
Rothwell JC, Hallett M, Berardelli A, Eisen A, Rossini P, Paulus W. Magnetic
stimulation: motor evoked potentials. The international federation of clinical
neurophysiology. Electroenceph Clin Neurophysiol Suppl 1999;52:97–103.
Sailer A, Molnar GF, Paradiso G, Gunraj CA, Lang AE, Chen R. Short and long latency
afferent inhibition in Parkinson’s disease. Brain 2003;126:1883–94.Sailer A, Cunic DI, Paradiso GO, Gunraj CA, Wagle-Shukla A, Moro E, Lozano AM,
Lang AE, Chen R. Subthalamic nucleus stimulation modulates afferent inhibition
in Parkinson disease. Neurology 2007;68:356–63.
Siebner HR, Tormos JM, Ceballos-Baumann AO, Auer C, Catala MD, Conrad B,
Pascual-Leone A. Low frequency repetitive transcranial magnetic stimulation of
the motor cortex in writer’s cramp. Neurology 1999;52:529–37.
Siebner HR, Mentschel C, Auer C, Lehner C, Conrad B. Repetitive transcranial
magnetic stimulation causes a short-term increase in the duration of the
cortical silent period in patients with Parkinson’s disease. Neurosci Lett
2000;284:147–50.
Siebner HR, Filipovic SR, Rowe JB, Cordivari C, Gerschlager W, Rothwell JC,
Frackowiak RSJ, Bhatia KP. Patients with focal arm dystonia have increased
sensitivity to slow-frequency repetitive TMS of the dorsal premotor cortex.
Brain 2003;126:2710–25.
Stinear CM, Byblow WD. Impaired modulation of corticospinal excitability
following subthreshold rTMS in focal hand dystonia. Hum Mov Sci
2004;23:527–38.
Strafella AP, Valzania F, Nassetti SA, Tropeani A, Bisulli A, Santangelo M, Tassinari
CA. Effects of chronic levodopa and pergolide treatment on cortical excitability
in patients with Parkinson’s disease: a transcranial magnetic stimulation study.
Clin Neurophysiol 2000;111:1198–202.
Tamburin S, Fiaschi A, Idone D, Lochner P, Manganotti P, Zanette G. Abnormal
sensorimotor integration is related to disease severity in Parkinson’s disease: a
TMS study. Mov Disord 2003;18:1316–24.
Tergau F, Naumann U, Paulus W, Steinhoff BJ. Low-frequency repetitive transcranial
magnetic stimulation improves intractable epilepsy. Lancet 1999;353:2209.
Valls-Solé J, Pascual-Leone A, Brasil-Neto JP, Cammarota A, McShane L, Hallett M.
Abnormal facilitation of the response to transcranial magnetic stimulation in
patients with Parkinson’s disease. Neurology 1994;44:735–41.
Valzania F, Strafella AP, Quatrale R, Santangelo M, Tropeani A, Lucchi D, Tassinari
CA, De Grandis D. Motor evoked responses to paired cortical magnetic
stimulation in Parkinson’s disease. Electroencephalogr Clin Neurophysiol
1997;105:37–43.
Wagle-Shukla A, Angel MJ, Zadikoff C, Enjati M, Gunraj C, Lang AE, Chen R. Low-
frequency repetitive transcranial magnetic stimulation for treatment of
levodopa-induced dyskinesias. Neurology 2007;68:704–5.
Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation:
report and suggested guidelines from the International Workshop on the Safety
of Repetitive Transcranial Magnetic Stimulation, June 5–7, 1996. Electroenceph
Clin Neurophysiol 1998;108:1–16.
Werhahn KJ, Kunesch E, Noachtar S, Benecke R, Classen J. Differential effects on
motorcortical inhibition induced by blockade of GABA uptake in humans. J
Physiol (Lond) 1999;517:591–7.
Wilson SA, Lockwood RJ, Thickbroom GW, Mastaglia FL. The muscle silent period
following transcranial magnetic cortical stimulation. J Neurol Sci
1993;114:216–22.
Ziemann U. TMS induced plasticity in human cortex. Rev Neurosci 2004;15:253–66.
Ziemann U, Tergau F, Bruns D, Baudewig J, Paulus W. Changes in human motor
cortex excitability induced by dopaminergic and anti-dopaminergic drugs.
Electroenceph Clin Neurophysiol 1997;105:430–7.
